Longevity Drug Index / SGLT2 inhibitors
SGLT2 inhibitors
Diabetes drugs that make the kidneys flush out sugar, protect the heart and kidneys, and extended lifespan in male mice.
How it works
SGLT2 is a transporter in the kidney that pulls glucose back into the blood. Blocking it means around 60 to 80 grams of glucose a day leave the body in urine. Blood sugar falls, people lose a little weight and fluid, and the body shifts towards burning fat and making ketones, a state that resembles mild fasting. The drugs also lower pressure inside the kidney’s filters.
How it could help longevity
Steady calorie loss and a fasting-like metabolism are thought to slow some aging processes. Just as importantly, these drugs protect the heart and kidneys, two organs whose decline drives much of the illness and death in later life.
Animal studies
- NIA Interventions Testing Program, 2020Canagliflozin given from 7 months of age increased median lifespan by about 14% in male mice. It did not extend lifespan in females.
- Health in old ageTreated mice had lower blood sugar after meals and fewer age-related lesions, and some benefits were seen when the drug was started late.
Human studies
- EMPA-REG OUTCOME, 2015In people with type 2 diabetes and heart disease, empagliflozin reduced cardiovascular deaths by 38% and deaths from any cause by 32%.
- Heart failure and kidney trials, 2019 onwardsTrials such as DAPA-HF, EMPEROR-Reduced and DAPA-CKD showed fewer hospitalisations and deaths, and slower kidney decline, even in people without diabetes.
- AgingNo completed trial has tested these drugs in healthy people for aging. The VITAL-H trial, funded by the US agency ARPA-H, will test dapagliflozin against placebo in adults in their 60s.
Safety and side effects
Genital yeast infections are common. The drugs can cause dehydration and low blood pressure, and rarely a dangerous form of ketoacidosis with normal blood sugar, especially around surgery, fasting or illness. Canagliflozin was linked to a higher amputation risk in one trial programme.
Our view
Strong human outcome data in people with diabetes, heart failure or kidney disease, plus a solid male mouse result. Whether they help healthy people age more slowly is untested.
Sources
- Miller et al., Aging Cell 2020: canagliflozin extends lifespan in male mice
- Zinman et al., NEJM 2015: EMPA-REG OUTCOME trial
- Heerspink et al., NEJM 2020: DAPA-CKD trial
- ClinicalTrials.gov: registered studies of SGLT2 inhibitors
Links open PubMed or ClinicalTrials.gov searches for each study.
Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.